康希诺生物

Information Disclosure

Home >Investor Relations >Information Disclosure

H Share

INSIDE INFORMATION PRELIMINARY PRICE CONSULTATION PERIOD OF PROPOSED ISSUE OF A SHARES AND SUMMARY OF PRINCIPAL PROVISIONS OF THE A SHARE PROSPECTUS
INSIDE INFORMATION COOPERATION WITH PFIZER TO PROMOTE MCV4 PRODUCT MENHYCIA
INSIDE INFORMATION COMPLETION OF REGISTRATION OF PROPOSED ISSUE OF A SHARES
INSIDE INFORMATION RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR) RECEIVED MILITARY SPECIALLY-NEEDED DRUG APPROVAL
Monthly Return of Equity Issuer on Movements in Securities
VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE MOVEMENT
INSIDE INFORMATION RESEARCH FINDINGS OF PHASE I CLINICAL TRIAL FOR RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR)
Monthly Return of Equity Issuer on Movements in Securities
CLARIFICATION ANNOUNCEMENT
INSIDE INFORMATION CLINICAL TRIAL APPLICATION APPROVAL IN CANADA FOR RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR)

1 41 42 43 44 45 52